<DOC>
	<DOCNO>NCT01369407</DOCNO>
	<brief_summary>REVIVAL establish prospective , observational , multicenter patient cohort ambulatory patient chronic , advanced , systolic heart failure provide great understanding clinical trajectory ( rate hospitalization , transplantation , MCSD use death ) , baseline clinical risk measure relate prognosis .</brief_summary>
	<brief_title>REGISTRY EVALUATION OF VITAL INFORMATION FOR VADs IN AMBULATORY LIFE</brief_title>
	<detailed_description>REVIVAL establish prospective , observational , multicenter patient cohort ambulatory patient chronic , advanced , systolic heart failure provide great understanding clinical trajectory ( rate hospitalization , transplantation , MCSD use death ) , baseline clinical risk measure relate prognosis . Within broad goal 1 ) improve prognostic assessment chronic , ambulatory , advance systolic heart failure , additional target goal 2 ) good inform selection appropriate candidate future study strategy early LVAD therapy vs. optimal medical management population , 3 ) determine feasibility identify candidate trial . Therefore , target population know high-risk feature increase mortality hospitalization ( e.g. , frequent hospitalization , reduce exercise capacity , elevate BNP N-terminal proBNP , increase Seattle Heart Failure Model risk score , reduce Heart Failure Survival Score ) . The REVIVE-IT Registry ( i.e. , REVIVAL ) prospective cohort study conduct twenty five ( 25 ) participate Clinical Sites USA . The study continue 400 eligible heart failure heart failure subject enrol ( estimate length accrual 12 month ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Ambulatory . 2 . Chronic systolic heart failure ≥ 12 month . 3 . NYHA II IV least 45 last 60 day . 4 . Last documented leave ventricular ejection fraction ≤ 35 % imaging modality . 5 . Age 18 80 year . 6 . Under care cardiologist study site . 7 . On appropriate evidence base heart failure medication ACE inhibitor , ARB sacubitril/valsartan [ LCZ696 ] ; beta blocker ; aldosterone antagonist ; hydralazine/longacting nitrate [ require AfricanAmerican subject ] ≥ 3 month absent contraindication intolerance . 8 . Has ICD CRTD . If CRTD , present ≥ 3 month . 9 . Demonstrated advanced heart failure , include one following* : i. Serum sodium ≤ 135 mEq/L ( obtained outpatient ) ** ii . Serum BNP ≥ 750 pg/mL NTproBNP ≥ 3000 pg/mL** ( obtained outpatient ) iii . Seattle Heart Failure Model ( SHFM ) one year predict survival ≤ 85 % ** iv . Heart Failure Survival Score ( HFSS ) ≤ 7.19** v. Peak VO2 ≤ 55 % predict age Wasserman equation ≤ 14 ml/kg/min , RER ≥ 1.05*** vi . VE/VC02 slope &gt; 40*** vii . 6 minute walk test ( 6MWT ) distance ≤ 350 without significant noncardiac limitation** viii . Currently list Heart Transplant Status II due heart failure limitation Or History one ( 1 ) hospitalization ( ≥ 24 hour ) acute acute chronic heart failure past year additional history include : i. Serum BNP ≥ 500 pg/mL NTproBNP ≥ 2000 pg/mL** ( obtained outpatient ) Or History two ( 2 ) hospitalization ( ≥ 24 hour ) acute acute chronic heart failure past year . * Qualifying measure must recent type measure obtain ( i.e. , BNP ≥ 1000 obtain 2 month prior would qualify heart failure subject recent BNP &lt; 1000 ) **Using value obtain within prior 90 day , except peak VO2 within 365 day ***Obtained within prior 365 day 10 . Willingness continue receive heart failure care enrol advanced heart failure clinic next two ( 2 ) year come schedule study visit . 12 . Written Informed consent give . 1 . Known serious medical problem heart failure would expect limit 2year survival ( ≥50 % mortality within 2 year nonheart failure diagnosis ) . 2 . Patient likely compliant protocol , opinion Investigator . 3 . Currently hospitalize . 4 . Current use intravenous inotrope . 5 . Primary functional limitation noncardiac diagnosis even likely limit survival . 6 . Chronic hemodialysis peritoneal dialysis serum creatinine value ≥ 3 mg/dL time enrollment . 7 . Cardiac amyloidosis , cardiac sarcoidosis , constrictive pericardial disease , active myocarditis congenital heart disease significant structural abnormality . 8 . Hypertrophic cardiomyopathy unless dilate LV outflow gradient . 9 . Cardiac condition amenable surgical percutaneous procedure ( VAD transplant ) would substantially improve prognosis subject reasonable candidate , regardless whether procedure perform . 10 . Uncorrected hyperthyroidism hypothyroidism . 11 . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>HF</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Heart Failure NYHA class III</keyword>
	<keyword>Advanced heart failure</keyword>
	<keyword>Systolic Heart Failure</keyword>
</DOC>